KNT-127, a chemically synthesized compound, helps suppress fear memories associated with PTSD, researchers report.
The Izhikevich neuron model allows the simulation of both periodic and quasi-periodic responses in neurons at lower computational cost.
Disulfiram, a drug commonly prescribed to treat chronic alcohol addiction, was shown to reduce anxiety levels in rodent models. The drug inhibits FROUNT protein and chemokine signaling pathways under its influence, suppressing overall glutamate transmission in the brain. This, in turn, helps reduce overall activity. The findings may signal a new way to treat anxiety in humans.
Mouse study reveals chronic stress affects neurogenesis in the dentate gyrus.
KNT-127 reduced anxiety-like behaviors in mice, researchers report.
Two medications commonly used to treat inflammation and HIV infection have been repurposed in the fight against COVID-19. Researchers found combined cepharanthine/nelfinavir therapy can hasten the clearance of coronavirus infection from a person's lungs in as little as 4.9 days. Cepharanthine hindered the entry of SARS_CoV_2 into cells, preventing the virus from binding to a protein on the cell membrane it uses as a gateway. Nelfinavir prevented the virus from replicating inside cells by inhibiting a protein the virus relies on for replication.
A genetic mutation of Caps2 impairs the release of oxytocin, leading to problems in regulating social behavior in those on the autism spectrum.
The stroke byproduct acrolein activates the precursor of heparanase, an enzyme that degrades the glycocalyx in the blood-brain barrier.
Oxytocin, the so-called "love hormone," could help to treat cognitive disorders, including Alzheimer's disease. Researchers demonstrated oxytocin reversed the effects of amyloid-beta on hippocampal LTP in mice. The findings suggest oxytocin could be used as a therapeutic for the treatment of Alzheimer's disease and other dementias.
Fully coupled artificial intelligence chip can solve the "Traveling Salesman Problem" for 22 cities instantly.
Far-infrared free-electron lasers may be a new way in which we fight the effects of Alzheimer's disease. Researchers report the technology can break down protein aggregates associated with the disease deep within the brain.
